Kristy Red-Horse

Kristy Red-Horse

Auto-generated profile, based on publicly available information

Kristy Red-Horse

Department of Biology, Stanford University

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2022 in Nature Reviews Cardiology
Verified
Journal Article
Closed access
PDF file
ETEmily Trimm
Emily Trimm
KRKristy Red-Horse
Kristy Red-Horse

4 July 2018 in Nature
Verified
Journal Article
Closed access
PDF file
TSTianying Su
Tianying Su
GSGeoff Stanley
Geoff Stanley
RSRahul Sinha
Rahul Sinha
GDGaetano D’amato
Gaetano D’amato
SDSoumya Das
Soumya Das
KRKristy Red-Horse
Kristy Red-Horse

1 December 2014 in Development
Verified
Journal Article
Closed access
PDF file
HCHeidi I. Chen
Heidi I. Chen
BSBikram Sharma
Bikram Sharma
BABrynn N. Akerberg
Brynn N. Akerberg
HNHarri J. Numi
Harri J. Numi
RKRiikka Kivelä
Riikka Kivelä
KRKristy Red-Horse
Kristy Red-Horse
Identifying coronary artery progenitors and their developmental pathways could inspire novel regenerative treatments for heart disease. Multiple sources of coronary vessels have been proposed, including the sinus venosus (SV), endocardium and proepicardium, but their relative contributions to the coronary circulation and the molecular mechanisms regulating their development are poorly understood. We created an ApjCreER mouse line as a lineage-tracing tool to map SV-derived vessels onto the heart and compared the resulting lineage pattern with endocardial and proepicardial contributions to the coronary circulation. The data showed a striking compartmentalization to coronary development. ApjCreER-traced vessels contributed to a large number of arteries, capillaries and veins on the dorsal and lateral sides of the heart. By contrast, untraced vessels predominated in the midline of the ventral aspect and ventricular septum, which are vessel populations primarily derived from the endocardium. The proepicardium gave rise to a smaller fraction of vessels spaced relatively uniformly throughout the ventricular walls. Dorsal (SV-derived) and ventral (endocardial-derived) coronary vessels developed in response to different growth signals. The absence of VEGFC, which is expressed in the epicardium, dramatically inhibited dorsal and lateral coronary growth but left vessels on the ventral side unaffected. We propose that complementary SV-derived and endocardial-derived migratory routes unite to form the coronary vasculature and that the former requires VEGFC, revealing its role as a tissue-specific mediator of blood endothelial development.

19 October 2015 in eLife
Verified
Journal Article
Open access
KVKatharina S Volz
Katharina S Volz
AJAndrew H Jacobs
Andrew H Jacobs
HCHeidi I Chen
Heidi I Chen
APAruna Poduri
Aruna Poduri
AMAndrew S McKay
Andrew S McKay
KRKristy Red-Horse
Kristy Red-Horse
Epicardial cells on the heart’s surface give rise to coronary artery smooth muscle cells (caSMCs) located deep in the myocardium. However, the differentiation steps between epicardial cells and caSMCs are unknown as are the final maturation signals at coronary arteries. Here, we use clonal analysis and lineage tracing to show that caSMCs derive from pericytes, mural cells associated with microvessels, and that these cells are present in adults. During development following the onset of blood flow, pericytes at arterial remodeling sites upregulate Notch3 while endothelial cells express Jagged-1. Deletion of Notch3 disrupts caSMC differentiation. Our data support a model wherein epicardial-derived pericytes populate the entire coronary microvasculature, but differentiate into caSMCs at arterial remodeling zones in response to Notch signaling. Our data are the first demonstration that pericytes are progenitors for smooth muscle, and their presence in adult hearts reveals a new potential cell type for targeting during cardiovascular disease.

1 February 2019 in Cell
Verified
Journal Article
Closed access
SDSoumyashree Das
Soumyashree Das
AGAndrew B. Goldstone
Andrew B. Goldstone
HWHanjay Wang
Hanjay Wang
JFJustin Farry
Justin Farry
GDGaetano D’aMato
Gaetano D’aMato
KRKristy Red-Horse
Kristy Red-Horse

28 August 2024 in Nature
Verified
Journal Article
Open access
PDF file
Jae Kyu RyuJae Kyu Ryu
Jae Kyu Ryu
ZYZhaoqi Yan
Zhaoqi Yan
MMMauricio Montano
Mauricio Montano
ESElif G. Sozmen
Elif G. Sozmen
KDKaruna Dixit
Karuna Dixit
KAKaterina Akassoglou
Katerina Akassoglou
Life-threatening thrombotic events and neurological symptoms are prevalent in COVID-19 and are persistent in patients with long COVID experiencing post-acute sequelae of SARS-CoV-2 infection1–4. Despite the clinical evidence1,5–7, the underlying mechanisms of coagulopathy in COVID-19 and its consequences in inflammation and neuropathology remain poorly understood and treatment options are insufficient. Fibrinogen, the central structural component of blood clots, is abundantly deposited in the lungs and brains of patients with COVID-19, correlates with disease severity and is a predictive biomarker for post-COVID-19 cognitive deficits1,5,8–10. Here we show that fibrin binds to the SARS-CoV-2 spike protein, forming proinflammatory blood clots that drive systemic thromboinflammation and neuropathology in COVID-19. Fibrin, acting through its inflammatory domain, is required for oxidative stress and macrophage activation in the lungs, whereas it suppresses natural killer cells, after SARS-CoV-2 infection. Fibrin promotes neuroinflammation and neuronal loss after infection, as well as innate immune activation in the brain and lungs independently of active infection. A monoclonal antibody targeting the inflammatory fibrin domain provides protection from microglial activation and neuronal injury, as well as from thromboinflammation in the lung after infection. Thus, fibrin drives inflammation and neuropathology in SARS-CoV-2 infection, and fibrin-targeting immunotherapy may represent a therapeutic intervention for patients with acute COVID-19 and long COVID.